Omega-3 Probe Underscores FTC Standard For Claims Substantiation
This article was originally published in The Tan Sheet
Executive Summary
FTC's widespread review of omega-3 fatty acid supplement claims reminds firms they must support claims with "competent and reliable scientific evidence," a standard stakeholders argue is unclear and at times impractical
You may also be interested in...
In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
Quality control problems for Johnson & Johnson's McNeil Consumer Healthcare business and the regulatory and congressional scrutiny that followed dominated the attention of drug and dietary supplement industry stakeholders in 2010.